AtriCure, Inc. vs Merck & Company, Inc. — Stock Comparison

ATRC
AtriCure, Inc.
$29.02
▲ 3.24%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
AtriCure, Inc.
ATRC6.7/10vs 6.7/10

Q·Score Breakdown

6.7
Neutral
Overall
6.7
Neutral
3.7
Quality
6.2
9.7
Health
7
7.5
Growth
6.2
6.3
Valuation
7.2
7.4
Sentiment
7.1
ATRC

Clean balance sheet with low leverage (0.2× debt-to-equity).

currently unprofitable (-2% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $46.75 (+61.1%)
8 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

ATRC
MRK
Trailing P/E
31.5×
78.5×
Forward P/E
11.5×
-2.1%
Profit Margin
13.6%
75.0%
Gross Margin
76.6%
-2.4%
ROE
13.1%
Revenue Growth
4.9%
Earnings Growth
1.43
Beta
0.28
Price / Book
$1.5B
Market Cap
$277.0B
$27 – $43
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →